Guggenheim Reiterates "Buy" Rating for Twist Bioscience (NASDAQ:TWST)

Twist Bioscience (NASDAQ:TWST - Get Free Report)'s stock had its "buy" rating restated by investment analysts at Guggenheim in a report released on Tuesday,Benzinga reports. They currently have a $50.00 target price on the stock. Guggenheim's price target points to a potential upside of 62.23% from the company's current price.

Other equities analysts also recently issued research reports about the company. Barclays lowered their price target on Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating on the stock in a report on Thursday, April 10th. Scotiabank reissued an "outperform" rating on shares of Twist Bioscience in a research report on Tuesday, February 4th. JPMorgan Chase & Co. dropped their price objective on shares of Twist Bioscience from $40.00 to $33.00 and set an "underweight" rating for the company in a research note on Tuesday, May 6th. Finally, Robert W. Baird cut their target price on Twist Bioscience from $54.00 to $44.00 and set an "outperform" rating for the company in a research report on Tuesday, May 6th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $50.40.

Twist Bioscience Stock Down 5.5 %

Shares of TWST traded down $1.79 during mid-day trading on Tuesday, reaching $30.82. The company's stock had a trading volume of 1,158,651 shares, compared to its average volume of 968,895. The company has a market cap of $1.85 billion, a price-to-earnings ratio of -9.12 and a beta of 2.54. The business has a fifty day moving average of $38.63 and a 200 day moving average of $43.69. The company has a quick ratio of 4.62, a current ratio of 4.96 and a debt-to-equity ratio of 0.03. Twist Bioscience has a 1 year low of $30.72 and a 1 year high of $60.90.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its quarterly earnings data on Monday, May 5th. The company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.56) by ($0.10). Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The company had revenue of $92.79 million during the quarter, compared to analyst estimates of $92.00 million. As a group, analysts forecast that Twist Bioscience will post -2.12 earnings per share for the current fiscal year.

Insider Buying and Selling at Twist Bioscience

In other Twist Bioscience news, SVP Paula Green sold 918 shares of the company's stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $40.91, for a total transaction of $37,555.38. Following the transaction, the senior vice president now directly owns 130,912 shares in the company, valued at approximately $5,355,609.92. This represents a 0.70 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Emily M. Leproust sold 2,402 shares of Twist Bioscience stock in a transaction that occurred on Thursday, March 6th. The stock was sold at an average price of $40.91, for a total transaction of $98,265.82. Following the sale, the chief executive officer now owns 662,692 shares of the company's stock, valued at approximately $27,110,729.72. This represents a 0.36 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 18,991 shares of company stock worth $742,654. Insiders own 3.01% of the company's stock.

Hedge Funds Weigh In On Twist Bioscience

Several large investors have recently bought and sold shares of the business. First Light Asset Management LLC bought a new stake in shares of Twist Bioscience during the 4th quarter valued at $56,984,000. Marshall Wace LLP increased its holdings in Twist Bioscience by 15,927.8% in the fourth quarter. Marshall Wace LLP now owns 846,107 shares of the company's stock valued at $39,319,000 after purchasing an additional 840,828 shares during the last quarter. ARK Investment Management LLC lifted its stake in Twist Bioscience by 11.5% in the first quarter. ARK Investment Management LLC now owns 6,241,595 shares of the company's stock valued at $245,045,000 after buying an additional 645,730 shares during the period. Thrivent Financial for Lutherans boosted its holdings in Twist Bioscience by 54.6% during the fourth quarter. Thrivent Financial for Lutherans now owns 1,505,753 shares of the company's stock worth $69,972,000 after buying an additional 532,040 shares during the last quarter. Finally, Jennison Associates LLC grew its position in shares of Twist Bioscience by 80.2% during the 4th quarter. Jennison Associates LLC now owns 680,778 shares of the company's stock worth $31,636,000 after buying an additional 302,884 shares during the period.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.